Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beyond the Stethoscope: Robotic Empathy in Pediatric Cardiology. The Emerging Role of Social Robots. A Pilot Study.

Pediatric cardiology·2026

Same author

Unraveling the Impact of COVID-19 Lockdowns on Youth Sports and Physical Activity: Insights From a Retrospective Cohort Study in Italy.

International journal of pediatrics·2025

Same author

Effective and safe use of alirocumab in spinal and bulbar muscular atrophy with high cardiovascular risk: a case report.

European review for medical and pharmacological sciences·2025

Same author

The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian Scientific Societies, guidelines on the diagnosis and management of erectile dysfunction.

Journal of endocrinological investigation·2023

Same author

Systematic review and meta-analysis on coronary calcifications in COVID-19.

Emergency radiology·2022

Same author

Healthcare professionals and patient information: a fresh look from the new italian law on consent.

La Clinica terapeutica·2021

Same journal

Mechanistic factors of cardiovascular diseases.

Minerva cardioangiologica·2020

Same journal

Robotic-assisted coronary artery bypass grafting: current knowledge and future perspectives.

Minerva cardioangiologica·2020

Same journal

Features of degenerative mitral valve prolapse in the North East of China: repair characteristics, and short-term follow-up results.

Minerva cardioangiologica·2020

Same journal

Myocardial revascularization in chronic coronary syndromes: does viability matter?

Minerva cardioangiologica·2020

Same journal

Extracorporeal membrane oxygenation for COVID-19: effective weapon or futile effort?

Minerva cardioangiologica·2020

Same journal

Heart and endurance sports: excesses are often unhealthy.

Minerva cardioangiologica·2020

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Paclitaxel eluting balloon: from bench to bedside.

R Marzullo¹, A Aprile, F Clementi

¹Department of Cardiology, Policlinic of Modena, Modena, Italy.

Minerva Cardioangiologica

|October 20, 2009

Summary

This summary is machine-generated.

Paclitaxel-eluting balloons (PEB) offer a promising strategy to combat in-stent restenosis, a common complication after coronary stenting. This review explores PEB technology and its effectiveness in reducing vascular tissue overgrowth.

More Related Videos

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: Jun 19, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

Interventional Cardiology
Vascular Biology
Drug Delivery Systems

Background:

Restenosis, or renarrowing inside stents, remains a significant challenge in interventional cardiology, affecting up to 25% of bare-metal stent and 10% of drug-eluting stent recipients.
Higher restenosis rates are observed in high-risk populations, including diabetics and patients with specific clinical or anatomical characteristics.
Current treatment modalities face limitations in fully addressing the issue of in-stent restenosis.

Purpose of the Study:

To review the characteristics of currently available paclitaxel-eluting balloon (PEB) devices.
To summarize the efficacy of PEBs in preclinical animal models and clinical studies for reducing restenosis.
To assess the potential applications of PEB technology in interventional cardiology.

Main Methods:

Literature review of paclitaxel-eluting balloon devices.
Analysis of data from animal studies investigating PEB performance.
Synthesis of results from clinical trials evaluating PEB use in patients.

Main Results:

Paclitaxel-eluting balloons represent a non-stent-based local drug delivery approach.
Evidence from animal models and clinical practice suggests PEBs can effectively reduce vascular tissue overgrowth and restenosis.
The technology shows promise for specific patient groups and lesion types at high risk for restenosis.

Conclusions:

Paclitaxel-eluting balloons are a viable and promising strategy to mitigate in-stent restenosis.
Further research and clinical application are warranted to define the optimal role of PEBs in interventional cardiology.
PEB technology has the potential to improve outcomes for patients undergoing percutaneous coronary interventions.